Treatment of Thymic Carcinoma at Masaoka-Koga Stage IVB (TNM Stage IVB) with Lymphogenous or Haematogenous Distant Metastasis

Clinical Scenario

This protocol applies to thymic carcinoma at Masaoka-Koga stage IVB (TNM stage IVB) — the most advanced stage of thymic epithelial tumour — defined by the presence of lymphogenous or haematogenous (distant) metastasis.

Stage IVB Disease Context

At stage IVB, disease is advanced, non-resectable, and metastatic. Systemic treatment as a single modality is indicated in patients whose tumour cannot be surgically removed or definitively irradiated.

Treatment Approach (Partial Overview)

In this setting, off-label targeted agents may be considered; eligibility and agent selection depend on specific clinical and molecular criteria. The complete list of options, the conditions governing their use, and the full treatment algorithm are available in the structured protocol.

Dosing, sequencing, and full selection criteria are not shown here — access the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/annonc/mdv277

Treatment algorithm for metastatic thymic tumour (Masaoka-Koga stage IVB, TNM stage IVB).
Chemotherapy should be offered as single modality treatment in advanced, non-resectable, non-irradiable or metastatic (stage IVB) thymic epithelial tumours.
Sunitinib may then represent an off-label option as second-line treatment of thymic carcinomas, independently from KIT status [III, A].
Everolimus may, therefore, represent an off-label option for refractory tumours [III, B].
It is not recommended to administer imatinib in the absence of a KIT-sensitising mutation, following the report showing the absence of activity in two phase II trials conducted in this setting [III, E].

View source ↗